PER

1.41%

7.0¢ percheron therapeutics limited

atl 1102 for DMD could be a Coy maker., page-2

First 2 Last

Share
Profile

Follow
monti901

964 Posts.

329

05/08/17

16:24

Post #: 26313009
Share

Originally posted by itsagas ↑

DMD.
ANP could be on a winner.Big $ to be made .Bio Marin paid $680 mill for a unproven drug.

BioMarin gambled $680 million in cash when it decided to buy Prosensa and its failed DMD drug drisapersen and make a bid to revive its prospects at the FDA. That effort was hit head on by the FDA’s rejection in early 2016. If BioMarin chooses to go for another exon-skipping drug, the company has rights to opt in on a co-exclusive deal with Sarepta...

ANP have enlisted a Board of international experts in DMD.......So Atl 1102 must have merit in the treatment for DMD.

The clinical trial of ATL1102 is planned to be undertaken at the Royal Children’s Hospital (RCH) in Melbourne, with the clinical development of ATL1102 in boys with DMD to be directed by an Advisory Board of international experts in the field. The Advisory Board is chaired by Mr William Goolsbee, a non-executive director of ANP and ex-Chairman of Sarepta Therapeutics (Sarepta are marketers of the antisense drug, eteplirsen, the first and only drug approved for the restoration of muscle dystrophin). Membership of the Advisory Board includes the Australian inventors of eteplirsen, Professor Steve Wilton and Professor Sue Fletcher (from Perth’s Western Australian Neuroscience Research Institute and Murdoch University respectively), and Dr Gillian Butler-Browne, Director, Centre of Research in Myology at Sorbonne University in Paris (whose team observed that circulating high CD49d expressing T- cells lead to poor prognosis in DMD patients).

Expand

DMD and MS partnerships for 1102 and another one for Acromegaly/1103 would obviously put ANP right up there as a takeover target for big pharma. Goolsbee has been bought on board to fastrack these agreements, he clearly has the credentials and contacts to make this happen. Eagerly awaiting a positive outcome... good luck to all holders...

ANP Price at posting: 3.7¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

BOE

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GRX

GreenX picks up prospective copper project in Germany

Is oil undervalued?

VMT

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

DVP

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

NXG

Cost blow-out for Rook I uranium project sees share plummet for NexGen

VMS

Venture to sniff out high-grade REE targets at Jupiter project, WA

MGU

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

WGX

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

There are more pages in this discussion • 73 more messages in this thread...

First 2 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 7.0¢		Change -0.001(1.41%)		Mkt cap ! $63.10M

Open	High	Low	Value	Volume
7.1¢	7.1¢	6.9¢	$34.01K	486.5K

Buyers (Bids)

No.	Vol.	Price($)
2	132919	6.9¢

Sellers (Offers)

Price($)	Vol.	No.
7.3¢	78000	1

View Market Depth

No.	Vol.	Price($)
1	80000	0.069
4	134427	0.068
3	224490	0.067
1	15000	0.066
4	32000	0.065

Price($)	Vol.	No.
0.073	78000	1
0.075	13371	1
0.078	75476	2
0.079	175123	2
0.080	287231	3

Last trade - 16.10pm 02/08/2024 (20 minute delay)

PER (ASX) Chart

atl 1102 for DMD could be a Coy maker., page-2

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Is oil undervalued?

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

atl 1102 for DMD could be a Coy maker., page-2

Top Stories

Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan

GreenX picks up prospective copper project in Germany

Is oil undervalued?

Vmoto sales plummet -50% YoY as weak demand in Europe & China stifles EV scooter sales growth

Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place

Cost blow-out for Rook I uranium project sees share plummet for NexGen

Venture to sniff out high-grade REE targets at Jupiter project, WA

Collaboration in a green (steel) future the focus for Magnum and Saudi partners

Westgold sets its sights on top five producer status through merger with Karora

Week 31 Wrap: JORC rules to get tougher; RBA rate hike chance 50/50; US Fed Sept cut still the quo

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News